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Strengths and limitations of this study
 ► The two- centre study investigates the combined im-
pact of arterial hypertension, bicuspid aortic valve 
disease and age on the presence, location and se-
verity of aortic distensibility impairment in patients 
with aortic coarctation.
 ► The study further characterises the effects of antihy-
pertensive treatment and adequate blood pressure 
control on aortic distensibility.
 ► Using observational cross- sectional data precludes 
the authors from directly inferring causal relation-
ships and individual longitudinal courses of disten-
sibility alterations.
AbStrACt
Objective We aimed to investigate the combined effects 
of arterial hypertension, bicuspid aortic valve disease 
(BAVD) and age on the distensibility of the ascending and 
descending aortas in patients with aortic coarctation.
Design Cross- sectional study.
Setting The study was conducted at two university 
medical centres, located in Berlin and London.
Participants A total of 121 patients with aortic 
coarctation (ages 1–71 years) underwent cardiac MRI, 
echocardiography and blood pressure measurements.
Outcome measures Cross- sectional diameters of the 
ascending and descending aortas were assessed to 
compute aortic area distensibility. Findings were compared 
with age- specific reference values. The study complied 
with the Strengthening the Reporting of Observational 
Studies in Epidemiology statement and reporting 
guidelines.
results Impaired distensibility (below fifth percentile) 
was seen in 37% of all patients with coarctation in the 
ascending aorta and in 43% in the descending aorta. BAVD 
(43%) and arterial hypertension (72%) were present across 
all ages. In patients >10 years distensibility impairment of 
the ascending aorta was predominantly associated with 
BAVD (OR 3.1, 95% CI 1.33 to 7.22, p=0.009). Distensibility 
impairment of the descending aorta was predominantly 
associated with arterial hypertension (OR 2.8, 95% CI 1.08 
to 7.2, p=0.033) and was most pronounced in patients 
with uncontrolled hypertension despite antihypertensive 
treatment.
Conclusion From early adolescence on, both arterial 
hypertension and BAVD have a major impact on aortic 
distensibility. Their specific effects differ in strength and 
localisation (descending vs ascending aorta). Moreover, 
adequate blood pressure control is associated with 
improved distensibility. These findings could contribute to 
the understanding of cardiovascular complications and the 
management of patients with aortic coarctation.
IntrODuCtIOn
Aortic coarctation (CoA) accounts for 
5%–10% of all congenital heart defects.1 
Despite progress made in early treatment 
concepts, morbidity and mortality remain 
high.2 Arterial hypertension (HTN) persists 
in more than 65% of all patients despite 
successful repair,1 3 commonly leading to 
cardiovascular and cerebrovascular compli-
cations and subsequently impaired long- term 
outcome.2 3 In up to 75% of cases4 CoA occurs 
in combination with bicuspid aortic valve 
disease (BAVD), which is also associated with 
vascular complications such as dilation of the 
aorta.
HTN, BAVD and age are each known to 
affect the distensibility of the aorta and thus 
on its Windkessel function that usually enables 
partial storage of left ventricular stroke 
volume during systole and the maintenance 
of continuous organ perfusion during dias-
tole. Persisting HTN has been demonstrated 
to be associated with impaired elastic capacity 
of the aorta5 and thus an increased afterload 
that can contribute to relevant cardiovas-
cular remodelling processes. In addition to 
HTN, the elasticity of the ascending aorta is 
frequently impaired in BAVD, as wall stresses6 
are typically elevated and elastic fibre content 
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of the medial layer decreases7 in the presence of perma-
nent non- laminar flow profiles. Furthermore, ageing has 
been shown to contribute to a loss of vascular elasticity 
throughout life.8
Although HTN, BAVD and age have each been associ-
ated with impaired elasticity, little is known about their 
combined impact. The specific impact of each risk factor 
on the impairment of vascular properties and the effects 
of antihypertensive treatment can be of clinical relevance. 
We therefore aimed to investigate the combined effects 
of HTN (with and without antihypertensive treatment), 
BAVD and age on the presence, location and severity 
of aortic distensibility impairment in patients with CoA 
using a non- invasive MRI- based approach.
MethODS
Study design, population and patient involvement
This observational study was carried out at two centres, 
located in Berlin, German Heart Centre Berlin (n=84) 
and London, University College London (n=37). The 
study population consisted of 121 consecutive outpatients 
with known CoA between January 2014 and December 
2016. Key inclusion criteria for the MRI study were (1) 
a confirmed diagnosis of CoA with (2) an indication for 
diagnostic evaluation according to European Society 
of Cardiology (ESC)9 and American College of Cardi-
ology/American Heart Association (ACC/AHA) guide-
lines10 due to (2A) echocardiography or blood pressure 
measurements indicating pressure gradients across the 
stenosis exceeding 20 mm Hg or (2B) severe narrowing 
and/or (2C) HTN that were (3) without relevant contra-
indications for MRI and were (4) without any additional 
complex congenital cardiovascular malformations. As 
this was a non- invasive study, MRI was also performed 
in patients with unclear treatment indications, where 
ESC and/or ACC/AHA guideline indications where 
suspected. The study complied with the Strengthening 
the Reporting of Observational Studies in Epidemiology 
statement.
In this study, all patients underwent echocardiog-
raphy and cardiac MRI in conjunction with blood pres-
sure measurements of the upper extremities. MRI- based 
approaches have recently been demonstrated to be 
feasible and reliable measures for non- invasive assess-
ment of aortic compliance and the resulting distensi-
bility in patients with CoA.11 12 Patients were considered 
hypertensive (HTN group) where the diagnosis of HTN 
was made according to clinical guidelines13 14 and with 
consideration of paediatric percentiles where appro-
priate.14 For all computations, blood pressures at the time 
of MRI examination in comfortably placed patients with 
back support for at least 5 min were used. Baseline char-
acteristics are shown in table 1.
The diagnosis of BAVD was made based on cine MRI 
data, acquired orthogonally to the native valve plane. 
Calculated aortic area distensibility was compared with 
percentiles of healthy individuals published by Voges et 
al.15 Distensibility impairment was defined as patients 
with measurements below the fifth percentile.
Patient and public involvement
We did not directly include patient and public involve-
ment in this study, but the research design has been moti-
vated by direct interactions and regular discussions with 
our patients. We are also sharing study results with partic-
ipants and provide a plain- language summary for patients 
and patient and public involvement representatives on 
request.
Image acquisition
Data were acquired on 1.5 T clinical MR systems (including 
Achieva; Philips Healthcare, Best, The Netherlands; and 
Avanto, Siemens, Erlangen, Germany). The cardiac MRI 
protocol included standard balanced fast field echo cine 
imaging with at least two slices covering the ascending 
and descending aortas to assess diameter changes for 
each vessel. The imaging planes were positioned perpen-
dicular to the vessel at the level of the pulmonary artery 
bifurcation. In case of imaging artefacts due to previous 
stenting, the plane covering the descending aorta was 
placed more distally, yet remained above the level of the 
diaphragm. Typical imaging parameters were: voxel size 
1.80×1.70×6 mm, reconstructed voxel size 1×1×6 mm, echo 
time=1.2 ms, repetition time=2.5 ms, flip angle 60°, retro-
spective cardiac gating, 40 automatically reconstructed 
cardiac phases. Scan duration in total was 9–14 min.
Image postprocessing and analysis
MRI cine images were analysed manually using View 
Forum (Philips Medical Systems Nederland; View Forum 
R6.3V1L7 SP1). Analysis was carried on- site for the respec-
tive patient group. The slices to be examined were manu-
ally selected at the level of pulmonary artery bifurcation 
(figure 1). Cross- sectional diameters of the ascending and 
descending aortas were measured during the end- systolic 
and end- diastolic heart phase, during the maximal and 
minimal expansion of the vessel. For each localisation, 
three slices nearby the point of maximal/minimal visual 
vessel extension were selected. For each measurement, 
three diameters were measured and the average was calcu-
lated. Diameters were chosen at the shortest distance and 
were subsequently converted to cross- sectional areas in 
order to minimise minor angulation errors. The arterial 
compliance is defined as the change in arterial blood 
volume (ΔV) relative to a given change in the arterial 
blood pressure (ΔP): C=ΔV/ΔP. Clinically, an alternative 
version of arterial compliance is used in which the cross- 
sectional area (A) of the aorta replaces the vessel volume. 
Aortic area compliance in this paper is defined as the 
change in the cross- sectional area of the aorta per unit of 




To achieve comparability within the study population, 
cross- sectional aortic area compliance was converted to 
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  Age (years) 22 (15;31) 22 (16;30) 23 (15;31) 0.760
  Male (n, %) 80 (66) 22 (65) 58 (67) 0.838
  Weight (kg) 66.2 (51;78) 59.25 (50.2;74) 68 (51;80) 0.183
  Height (cm) 169 (153;177.5) 167 (152.6;178) 170 (153;177.5) 0.674
  BMI (kg/m²) 22.3 (19.36;25.16) 21.24 (19.36;23.72) 22.64 (19.1;25.3) 0.324
  BSA (m²) 1.74 (1.5;1.95) 1.66 (1.47;1.93) 1.8 (1.47;1.97) 0.190
  Bicuspid aortic valve (n, %) 52/121 (43) 15/34 (44) 37/87 (43) 0.874
  Previous episodes of HTN and/or exercise HTN (n, %) 98/121 (81) 11/34 (32) 87/87 (100) 0.002
  Systolic BP (mm Hg) 136 (122;148) 116 (110;122) 142 (134;152) <0.001
  Diastolic BP (mm Hg) 69 (62;77) 66.5 (58;75) 72 (63;80) 0.006
  Echocardiographic pressure drop across stenosis (mm 
Hg)
25 (13;41) 25 (13;35) 25 (14;45) 0.289
  Patients with echocardiographic pressure drop above 
20 mm Hg (n, %)
81 (67) 23 (68) 58 (67) 0.918
Previous treatment
  Balloon angioplasty (n, %) 45/121 (37) 9/34 (26) 36/87 (41) 0.129
  Stenting (n, %) 23/121 (19) 4/34 (12) 19/87 (22) 0.206
  Surgical reconstruction (n, %) 73/121 (60) 23/34 (68) 50/87 (57) 0.306
  Antihypertensive medication (n, %) 37/121 (31) 11/34 (32) 26/87 (30) 0.791
Type of medication
  Beta blockers (n, %) 23/121 (19) 7/34 (21) 16/87 (18) 0.783
  ACE inhibitors (n, %) 22/121 (18) 7/34 (21) 15/87 (17) 0.669
  Calcium channel blockers (n, %) 11/121 (9) 1/34 (3) 10/87 (11) 0.143
  Angiotensin receptor blockers (n, %) 4/121 (3) 1/34 (3) 3/87 (3) 0.889
  Diuretics (n, %) 7/121 (6) 3/34 (9) 4/87 (5) 0.373
Diameter of the aorta
  Ascending aorta, minimum (mm) 25 (19.9;30) 26.05 (19.2;30) 24.2 (20;30.3) 0.802
  Ascending aorta, maximum (mm) 29.09 (24;33.1) 29.45 (24;32.7) 28.4 (23.8;33.8) 0.762
  Descending aorta, minimum (mm) 17.9 (14.7;20.9) 16.84 (13.8;20.3) 17.9 (15;21) 0.378
  Descending aorta, maximum (mm) 20 (16.2;23.3) 19.25 (15.8;23) 20.1 (16.2;23.4) 0.500
Pressure drop across the stenosis: maximal pressure in mm Hg across the coarctated segment measured by echocardiography; 
ascending and descending aortas (minimum) describing end- diastolic cross- sectional diameter; ascending and descending aortas 
(maximum) describing end- systolic cross- sectional diameter.
Continuous data are expressed as median and IQR (Q1;Q3), p values are from Wilcoxon- Mann- Whitney test. Categorical data are 
presented as frequencies and percentage (%), p values are from Pearson’s χ2 test.
BMI, body mass index; BP, blood pressure; BSA, body surface area; HTN, hypertension.
area distensibility (Darea), defined as the relative change 







= Amax−AminAmin × 1PP  
Amax represents the systolic cross- sectional area and 
Amin the diastolic area. PP is defined as the difference 
between systolic and diastolic pressure (Psystolic–Pdiastolic). 
Previous studies have demonstrated12 that a non- invasive 
sphygmomanometer- based blood pressure measurement 
on the left arm can be expected to be higher than aortic 
PP. Hence, we used a linear model for generating the 
aortic PP with given values such as mean arterial pressure 
(MAP)  
(




  and PP measured by 
cuff on the left arm (PPLA), as described in Kelm et al
12:









The linear model is only valid on the condition that the 
aortic PP is less than or equal to peripheral PP.
Statistical analysis
Continuous data are expressed as median and IQR 
(Q1;Q3) unless stated otherwise. Categorical data are 
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Figure 1 Locations of cross- sectional diameter 
measurements of the ascending and descending aortas, 
measured during the end- systolic and end- diastolic heart 
phase
presented as frequencies and percentages (%). Data 
distribution was tested using Shapiro- Wilk and Shapiro- 
Francia tests. Wilcoxon- Mann- Whitney test was used to 
assess continuous data for differences between groups 
(HTN vs non- HTN). Pearson’s χ2 test was used in 
conjunction with Fisher’s exact test to compare categor-
ical variables between groups. Non- parametric regres-
sion was performed to assess multifactorial effects on 
the distensibility of the aorta. Multifactorial influences 
leading to distensibility impairment were assessed using 
logistic regression. Predictive margins were calculated 
and plotted to visualise the combined effects of BAVD, 
HTN, medication and age. Stata V.15.1 was used for statis-
tical analysis. P values <0.05 were considered statistically 
significant.
reSultS
A two- centre cohort of patients with CoA was included 
in the analysis, in which the patient populations did not 
significantly differ between the participating centres. 
Seventy- two per cent (87/121) of patients were hyperten-
sive at the time of examination. BAVD was found in 43% 
(52/121) of subjects. Patient characteristics of the study 
population divided into the two groups (HTN group and 
non- HTN group) are shown in table 1. There were no 
significant differences between the two groups regarding 
patients’ characteristics or previous treatment. Median 
echocardiographic pressure gradients and the number of 
patients with a pressure drop above 20 mm Hg did not 
differ between groups.
In patients above the age of 10 years, aortic distensi-
bility of the ascending and descending aortas decreased 
with age (figure 2). While no significant differences 
in distensibility of the ascending aorta were found 
between normotensive patients and patients with HTN 
(figure 2A), a multifactorial model revealed that patients 
with HTN and CoA above the age of 10 years showed 
significantly lower distensibility of the descending aorta 
compared with normotensive subjects in their age groups 
(figure 2B). In patients with CoA and coexisting BAVD 
older than 10 years of age, distensibility of the ascending 
aorta was significantly lower than patients with tricuspid 
aortic valve (figure 2C), while BAVD showed no impact 
on the distensibility of the descending aorta (figure 2D). 
These effects were not found in patients below the age of 
10 years.
Of the total cohort, 37 patients were under antihy-
pertensive medication. From these patients, 19 were 
on monotherapy and 18 were on dual or triple therapy. 
Compared with normotensive patients without anti-
hypertensive medication, the estimated distensibility 
of the descending aorta was (1) significantly lower in 
normotensive patients, who were under antihyperten-
sive treatment at the time of examination (estimated 
effect: −1.32×10–3 mm Hg–1, p=0.031). Furthermore (2), 
in patients with HTN without antihypertensive medica-
tion even further reduced distensibility of the descending 
aorta (estimated effect: −2.43×10–3 mm Hg–1, p=0.020) 
was found, and (3) was lowest in patients with HTN and 
CoA under antihypertensive medication, that is, patients 
with uncontrolled HTN despite therapy (estimated 
effect: −3.40×10–3 mm Hg–1, p=0.022). There were no 
drug- specific effects on distensibility of the ascending or 
descending aorta. The effects are illustrated in figure 3. 
No significant differences were found between previous 
surgical or interventional treatment.
In comparison to reference data from healthy individ-
uals,15 distensibility impairment below the fifth percen-
tile was found in the ascending aorta in 37.2% and in 
the descending aorta in 43.0% of all patients with CoA. 
Patients with CoA with a combination of BAVD and HTN 
had impaired distensibility of the ascending aorta in 
49.6% and distensibility impairment of the descending 
aorta in 51.4%. In normotensive patients with CoA and 
physiological tricuspid valve, impaired distensibility was 
present in just 21.1% in the ascending aorta and 26.3% in 
the descending aorta.
In patients below 10 years of age, no associations were 
found between BAVD and impaired distensibility in the 
ascending (p=0.519) or the descending (p=0.889) aorta. 
Also, HTN and impaired distensibility showed no signif-
icant correlation, either in the ascending (p=0.635) or 
in the descending (p=0.207) aorta. In patients above the 
age of 10 years, distensibility impairment of the ascending 
aorta was more common in BAVD (OR 3.1, 95% CI 1.33 
to 7.22, p=0.009). In these patients with BAVD, impaired 
distensibility of the ascending aorta was seen in 51.1%, 
compared with 26.9% in patients with a tricuspid valve. 
Associations between BAVD and impaired distensibility of 
the ascending aorta further increased with age, whereas 
no such associations were found in the descending aorta. 
Patients with HTN above the age of 10 years showed no 
association with distensibility impairment in the ascending 
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Figure 2 Aortic distensibility of the ascending aorta (left) and descending aorta (right) in patients with or without accompanying 
HTN or BAVD, plotted against age. It includes the effects of (A) HTN on the ascending aorta, (B) HTN on the descending 
aorta, (C) BAVD on the ascending aorta and (D) BAVD on the descending aorta; BAVD, bicuspid aortic valve disease; HTN, 
hypertension.
Figure 3 Estimated effects of antihypertensive medication 
on the distensibility of the descending aorta, compared with 
normotensive patients without medication (reference).
aorta (p=0.239), whereas distensibility impairment of 
the descending aorta was correlated with HTN (OR 2.8, 
95% CI 1.08 to 7.2, p=0.033). Distensibility impairment of 
the descending aorta below the fifth percentile was seen 
in 49.3% of all patients with HTN >10 years, compared 
with 26.7% in normotensive patients.
The combined impact of BAVD and HTN on disten-
sibility impairment below the fifth percentile in patients 
with CoA aged 10–50 years is shown in figure 4. In patients 
with HTN, 95% CIs of the estimated risk for distensibility 
impairment of the descending aorta did not overlap from 
the age of 30 years onwards. In patients with BAVD, the 
same effects were observed for the ascending aorta in 
patients above 30 years.
Significant differences in cross- sectional diameters of 
the ascending aorta between patients with BAVD and 
patients with tricuspid valve and CoA were observed. 
Compared with patients with tricuspid aortic valve, those 
with BAVD had significantly larger end- diastolic and 
end- systolic diameters of the ascending aorta: minimum 
22.6 (18.9;28.5) mm in tricuspid valve morphology vs 28 
(22.3;36.1) mm in BAVD, p<0.001; maximum 27 (21.9;31) 
mm vs 30.7 (24.9;38.7) mm in BAVD, p=0.002.
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Figure 4 Marginal effects and 95% CIs for impaired aortic distensibility (below the fifth percentile) of the ascending and 
descending aortas, in patients with or without hypertension (HTN) or bicuspid aortic valve disease (BAVD), plotted against age 
(*p<0.05; **p<0.01).
DISCuSSIOn
In our cohort, aortic distensibility was impaired in 
almost half of all patients with CoA. In those above the 
age of 10 years, BAVD had a significant effect on disten-
sibility impairment of the ascending aorta, whereas 
HTN predominantly affected the descending aorta. 
Additionally, antihypertensive treatment was associated 
with improved distensibility. However, when compared 
with normotensive patients without medical treatment, 
normotensive patients under antihypertensive medica-
tion had significantly lower distensibility across all ages. 
Distensibility was even lower in untreated patients with 
HTN, and lowest in those with uncontrolled HTN despite 
antihypertensive therapy.
Increased aortic stiffness (impairment of the Wind-
kessel capacity) is considered as a marker for vascular 
disease and cardiovascular outcome.16 An example 
can demonstrate the immediate impact of reduced 
distensibility on Windkessel capacity: in a 30- year- old 
male patient with physiological (50th percentile) 
distensibility of the ascending (7.5×10–3 mm Hg−1) and 
descending (5.5×10–3 mm Hg−1) aortas, the expected 
overall Windkessel volume of the thoracic aorta is 
33.2 mL. With impaired distensibility (below the fifth 
percentile), the Windkessel volume of the thoracic 
aorta would decrease by approximately one- third to 
22.2 mL (−33.13%). This can induce various severe 
consequences for blood circulation in the cardiovas-
cular system, such as increases in systolic blood pressure 
and cardiac afterload, diminished diastolic function17 
and coronary blood flow,18 and left ventricular hyper-
trophy.17 High systolic pressure was found to directly 
result in fractures of the elastic laminae and an increase 
in collagen fibres, further accelerating the loss of arte-
rial elasticity, ultimately leading to vascular dysfunction, 
heart failure and cardiovascular events.19
Distensibility impairment in our cohort was most 
clearly observed in patients above the age of 10 years. 
This supports a concept of aortic distensibility in which 
the duration a patient is exposed to risk factors can be 
crucial for the development of distensibility impairment 
and thus for the likelihood of subsequent cardiovas-
cular events. In line with these findings, increased wall 
stiffening in patients with CoA and prolonged exposure 
to abnormal haemodynamics was recently suggested.20 
However, despite early surgical repair, the distensibility 
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of the aorta can remain impaired in CoA, as has been 
observed in patients with tetralogy of Fallot.21 22
A previous study showed that the development of 
postoperative systemic HTN depends on the duration 
of preoperative HTN in CoA23 and suggested that the 
extent of decrease in aortic distensibility is related to the 
patients’ age at surgery.24 Possible concepts of the under-
lying pathophysiology include an ongoing remodelling 
process of the pressure- sensitive baroreceptors located in 
the aortic arch, which adapt to the limited contractility 
of the vessel wall and higher pressure states over time.25 
Preoperative HTN and a lack of normalisation due to, for 
example, inadequate antihypertensive treatment after 
surgical repair may be important causes of subsequent 
loss of aortic elasticity and thus cardiovascular compli-
cations in patients with CoA. In accordance with these 
concepts, our data show the most impaired distensibility 
values among patients with uncontrolled HTN despite 
antihypertensive therapy, whereas well- adjusted blood 
pressures at the time of the study were associated with 
improved aortic distensibility of the descending aorta. 
There is a lack of longitudinal studies regarding the 
reversibility of distensibility impairment under antihyper-
tensive medication in patients with CoA. However, it has 
been shown that adequate HTN control may also prevent 
HTN- related complications,13 such as coronary artery 
disease, sudden cardiac death, heart failure and cerebro-
vascular accidents.3
Patients with BAVD are known to be affected by severe 
alterations in flow profiles26 and degenerative changes 
in the tunica media of the ascending aorta, which also 
influence the elasticity of the aorta.7 27 Previous studies 
have shown increased regional wall shear stress in the 
ascending aorta of patients with BAVD to correspond with 
extracellular matrix dysregulation and elastic fibre degen-
eration.6 The bicuspid valve may further contribute by 
speeding up the progression of aortic wall complications 
such as aortic dilatation,27 aneurysm, rupture and dissec-
tion.28 Dilated and aneurysmatic areas in BAVD were 
previously reported to show reduced aortic elasticity.29
Our results confirm significantly impaired distensibility 
of the ascending aorta in patients with CoA and BAVD 
where aortic dilation was present, starting in childhood. 
The high prevalence of BAVD and its association with dila-
tation may superimpose the effects of HTN on the disten-
sibility impairment of the ascending aorta. However, in 
patients with tricuspid valves, effects of HTN were equally 
limited to the descending aorta. The high risk for distensi-
bility impairment of the ascending aorta suggests that the 
presence and severity of BAVD and associated turbulent 
flow may be important contributors to vascular pathology.
Several techniques have been introduced to assess 
vascular properties, including invasive intravascular 
ultrasound,30 CT angiography,31 echocardiography, 
pulse wave velocity (PWV) and MRI.32 While peripheral 
PWV measures can be non- invasive and easily applied, 
they are unsuitable in patients with vascular stenosis, 
as the narrowing can be a relevant source of error due 
to abnormal wave reflections.12 In contrast to PWV as a 
current reference standard for assessing arterial stiff-
ness,32 the area distensibility used in this study allows 
localised quantification of elastic capacity,33 regardless of 
the presence of a stenosis. Although the calculation of the 
area compliance is a relatively new method, its reliability 
has been previously demonstrated in CoA.12
limitations
The calculation of area distensibility depends on manual 
postprocessing of cardiac imaging data, and there-
fore individual experience as well as training can be 
essential for precise measurements. To ensure compa-
rability and consistency of aortic compliance and disten-
sibility measurements, the interobserver variability has 
been assessed.34 To reduce the risk of overestimating 
vessel diameters, angulation errors were reduced using 
minimal cross- sectional diameters of the vessel. Further-
more, central blood pressure estimations are required 
for distensibility calculation and were not directly 
assessed by invasive heart catheterisation. To allow a non- 
invasive assessment, we used a previously described cuff 
pressure- based model for central PP estimation33 that 
has been tested in patients with CoA.12 All blood pres-
sure measurements were simultaneously obtained to MRI 
measurements.
The cross- sectional study was not designed to identify 
a specific age cut- off. The age of 10 years (from which 
significant associations were found within our model) is 
only descriptive for our study cohort. Longitudinal studies 
and larger cohorts are required to assess to which extent 
these mechanisms apply in principle and why they are 
more pronounced in adolescents and adults. Moreover, 
the study was not intended to assess subgroups of hetero-
geneous previous interventional or surgical techniques.
The comparison of aortic distensibility in CoA with 
healthy individuals was based on published percentiles by 
Voges et al. The comparability was ensured by considering 
the used methods, including sequence parameters as well 
as data analysis workflow. Published percentiles covered 
age ranges from 2 to 30 years. As our cohort included 
older patients, percentile graphs were extrapolated for 
older patients.
COnCluSIOn
From early adolescence on, BAVD and HTN were both 
associated with an impairment of aortic distensibility in 
patients with CoA. Their specific effects differ in strength 
and localisation: BAVD had its main effect on the disten-
sibility of the ascending aorta, whereas HTN affected the 
distensibility of the descending aorta. Whether antihy-
pertensive medication is capable of preventing the onset 
or reversing existing distensibility impairment remains 
unclear. However, adequate blood pressure control was 
associated with improved distensibility. Therefore, anti-
hypertensive treatment and the early non- invasive detec-
tion of alterations may be pertinent strategies for the 
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prevention and reduction of distensibility impairment of 
the aorta.
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